拉米夫定联合TACE治疗原发性肝癌临床观察  

Treatment efficiency of Lamivudine and TACE in primary heptatic carcinoma patients

作　　者：李月华[1] 易琼[1] 罗永红[1] 黄宇[1] 

机构地区：[1]四川大学华西医院肿瘤科,成都610041

出　　处：《现代仪器与医疗》2013年第2期81-82,77,共3页Modern Instruments & Medical Treatment

摘　　要：目的研究拉米夫定联合经皮肝动脉栓塞化疗术(Transcatheter arterial chemoembolization,TACE)治疗HBV-DNA阳性肝癌的疗效。方法选取我院住院患者102例原发性肝癌患者为研究对象,分为TACE+拉米夫定治疗组(50例),TACE对照组(52例),分别进行治疗,观察2组患者HBV-DNA水平、肝功能指标和child评分。结果治疗组HBV-DNA水平、肝功能指标和治疗效果均优于对照组,差异具有显著性(P<0.05)。结论拉米夫定联合TACE治疗乙肝病毒相关性肝癌患者,可抑制病毒复制,提高治疗效果。Objective To observe the effect of Lamivudine Capsules combined with transcatheter arterial chemoembolization in the treatment of primary hepatic carcinoma. Methods Randomly divide 102 cases of primary hepatic carcinoma patients into two group, treatment group is with TACE combined with Lamivudine in treatment and control group is treat with TACE therapy. Observe the HBV-DNA, ALT and 2-year survival rate index. Results HBV-DNA, ALT and 2-year survival rate of treatment group is better than control group ,the difference between the two group is significant （P〈0.05）. Conclusion Lamivudine combined TACE treatment have good efficiency on primary hepatic carcinoma patients, and worth further promotion

关 键 词：拉米夫定 经皮肝动脉栓塞化疗术 疗效观察 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]